HOME >> BIOLOGY >> NEWS
Common cause of heart disease, diabetes may be treatable with malaria drug

Studies of a rare genetic condition that increases cancer risk have unveiled a potential treatment for metabolic syndrome, a common disorder that afflicts as many as one in every four American adults and puts them at sharply increased risk of type 2 diabetes and clogged arteries.

Scientists know relatively little about metabolic syndrome, which is linked to a range of symptoms that include obesity, insulin resistance, high blood pressure, low levels of good cholesterol and high blood sugar levels. The number of adults and children with the condition is rising sharply in industrial countries, and diagnoses are also increasing in developing countries like India and China as they adopt Western standards of living.

In findings published in the November issue of Cell Metabolism, researchers at Washington University School of Medicine in St. Louis and St. Jude Children's Research Hospital in Memphis, Tenn. report that a small dose of the malaria drug chloroquine eased many symptoms of metabolic syndrome in mice, reducing blood pressure, decreasing hardening and narrowing of the arteries and improving blood sugar tolerance.

"We just received funding for a clinical trial, and we're very excited to see if the processes activated by chloroquine can effectively treat one of the most common health problems of modern industrialized society," says senior author Clay F. Semenkovich, M.D., professor of medicine and of cell biology and physiology at Washington University. "We already know that chloroquine is safe and well-tolerated, and our mouse results suggest we may only need very low and perhaps infrequent doses to achieve similar effects in humans."

Researchers elsewhere proposed recently that high doses of the anti-aging molecule resveratrol might similarly treat obesity and metabolic syndrome. However, it is unclear if such high doses are safe, and scientists know relatively little about how resveratrol is easing symptoms.


'"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
7-Nov-2006


Page: 1 2 3

Related biology news :

1. Common environmental chemicals in diet affect fetal ovarian development
2. Common cancer gene sends death order to tiny killer
3. Common treatment for methamphetamine overdose may damage brain cells
4. Common genetic variation is linked to substantial risk for heart attack
5. Common fungicide causes long-term changes in mating behavior
6. DNA ends: Common tool, different job
7. Common gene version optimizes thinking -- but with a possible downside
8. Common mechanisms for viral DNA replication
9. Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia
10. Commonplace sugar compound silences seizures
11. Common garden plant threatened by climate change

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/30/2019)... ... October 29, 2019 , ... LGC Maine ... ATELLICA® analyzers, Order Numbers 701sa & 704sa. The kits, in a human-urine matrix, ... UUN. , Each VALIDATE® kit, liquid, ready-to-use, and prepared using the CLSI EP06-A ...
(Date:10/29/2019)... ... October 29, 2019 , ... Fujirebio Diagnostics, Inc., a ... (FDA) clearance of the company’s Lumipulse® G whole PTH Assay for testing on ... by the parathyroid glands; which are four small glands located behind the thyroid ...
(Date:10/26/2019)... ... October 23, 2019 , ... Nanovis today announced that ... the FDA requirements for nanotechnology. , “We are delighted to receive such ... important role in achieving Nanovis’ goal to reduce the pain and suffering from ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... ... November 06, 2019 , ... Diversified Technologies, Inc. has ... and vegetables per hour to improve processing. , The DTI Industrial PEF Unit can ... hour to increase juice yields by up to 50% and achieve up to an ...
(Date:11/2/2019)... (PRWEB) , ... October 31, 2019 , ... ... not always used to communicating with each other: study managers, principal investigators, supply ... misunderstandings if a party is not informed of the latest data, potentially leading ...
(Date:10/29/2019)... Conn. (PRWEB) , ... October 28, 2019 , ... ... Advisory Board: , , Professor Jack R Wands, MD, of ... and Wyeth (Pfizer) , Professor Gil Mor, MD, PhD, of Wayne State ...
(Date:10/22/2019)... N.J. (PRWEB) , ... October 22, 2019 , ... Catalent, ... Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel session ... Conference (HPCLC), to be held at the Gwen Hotel, Chicago, on Oct. 28-30, 2019. ...
Breaking Biology Technology:
Cached News: